Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C

Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C

Combination treatment of ledipasvir and sofosbuvir (LDV/SOF) is first‐line treatment for patients with chronic hepatitis C genotype 1 in the United States, Europe, and Japan. However, the influence of LDV/SOF on the cardiovascular system is poorly characterized. A total of 470 chronic hepatitis C pa...

Full description

Bibliographic Details
Main Authors:	Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, Naoki Morishita, Ryoko Yamada, Takayuki Yakushijin, Naoki Hiramatsu, Yoshinori Doi, Akira Kaneko, Hideki Hagiwara, Yukinori Yamada, Taizo Hijioka, Masami Inada, Shinji Tamura, Yasuharu Imai, Kunimaro Furuta, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara
Format:	Article
Language:	English
Published:	Wiley 2018-08-01
Series:	Hepatology Communications
Online Access:	https://doi.org/10.1002/hep4.1206

Similar Items

Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
by: Naoki Morishita, et al.
Published: (2020-01-01)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
by: Resmi Premji MD, et al.
Published: (2015-12-01)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
by: Jona T Stahmeyer, et al.
Published: (2017-01-01)

Daclatasvir/Sofosbuvir versus Ledipasvir/Sofosbuvir in Patients with Hepatitis C Virus Infection Genotypes 1 and 3
by: Narjes Shokatpour, et al.
Published: (2020-06-01)

CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma
by: Shigeki Suemura, et al.
Published: (2019-09-01)

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir
by: Sachiko Omotani, et al.
Published: (2020-04-01)

Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)
by: Sergio Vicente-Sánchez, et al.
Published: (2017-03-01)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
by: Yang CHT, et al.
Published: (2018-07-01)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
by: Umer Ansari, BS, et al.
Published: (2017-01-01)

Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents
by: Jesús Quintero, et al.
Published: (2019-03-01)

CEACAM1 Is Associated With the Suppression of Natural Killer Cell Function in Patients With Chronic Hepatitis C
by: Takahiro Suda, et al.
Published: (2018-10-01)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
by: Peter Buggisch, et al.
Published: (2019-01-01)

Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment
by: Bashar Aqel, et al.
Published: (2018-09-01)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
by: Sundaram V, et al.
Published: (2016-06-01)

Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.
by: Seiichi Tawara, et al.
Published: (2016-01-01)

Ledipasvir/sofosbuvir induced nephrotic syndrome: A challenging case of Hepatitis C management
by: Zaver, Himesh, et al.
Published: (2018)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
by: Naylor PH, et al.
Published: (2017-03-01)

Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients
by: Shih-Jer Hsu, et al.
Published: (2020-03-01)

Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report
by: Giovanni Covini, et al.
Published: (2018-10-01)

RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS
by: S. V. Zhavoronok, et al.
Published: (2018-10-01)

Simultaneous chromatographic analysis of Sofosbuvir/Ledipasvir in their combined dosage form: an application to green analytical chemistry
by: Ahmed Hemdan, et al.
Published: (2019-12-01)

Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
by: Jennifer S. Husson, MD, MPH, et al.
Published: (2017-12-01)

Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir
by: Patrick R. Brown, et al.
Published: (2018-10-01)

The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis
by: William Stokes, et al.
Published: (2017-01-01)

Cardiac arrhythmia due to ledipasvir/sofosbuvir Iranian counterpart, commercially named as Ledibiox: A case report
by: Alireza Heidari Bakavoli, et al.
Published: (2020-09-01)

The efficacy and safety of sofosbuvir/ledipasvir therapy in patients on long-term hemodialysis with hepatitis C virus infection
by: G Li Cavoli, et al.
Published: (2018-01-01)

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective
by: Nkuize M, et al.
Published: (2016-06-01)

Combinación de ledipasvir/sofosbuvir como tratamiento de la infección crónica por hepatitis C
by: Jesús Quintero, et al.
Published: (2019-03-01)

Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis
by: Xue Yang, et al.
Published: (2021-07-01)

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study
by: Catherine A Chappell, MD, et al.
Published: (2020-09-01)

Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
by: Vincent Alcazer, et al.
Published: (2018-12-01)

Ledipasvir and sofosbuvir for treatment of post- renal transplant hepatitis C infection: A case report withreview of literature
by: R Jha, et al.
Published: (2016-01-01)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
by: Mohammed A Babatin, et al.
Published: (2019-01-01)

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4
by: Nadia Marascio, et al.
Published: (2019-05-01)

An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function
by: Shyam Patel, et al.
Published: (2016-01-01)

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis
by: Mohammad Saeid Rezaee-Zavareh, et al.
Published: (2017-03-01)

Increased Bcl-xL Expression in Pancreatic Neoplasia Promotes Carcinogenesis by Inhibiting Senescence and ApoptosisSummary
by: Kenji Ikezawa, et al.
Published: (2017-07-01)

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
by: Gregory D Huhn, et al.
Published: (2020-01-01)

Delayed-Type Hypersensitivity Reaction to Red Tattoo Ink Triggered by Ledipasvir/Sofosbuvir for Hepatitis C: A Case Report
by: Meghan L. McPhie, et al.
Published: (2021-07-01)

Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan
by: Hung-Chih Chiu, et al.
Published: (2021-03-01)